Children's Medical Center Corporation

Frederick W Alt

Hwei-Ling Cheng

Ming Tian

Roberto Chiarle

Monica Gostissa

Raul Mostoslavsky

Robin M Meyers

Jiazhi Hu

Zhang Yu

Yu Zhang

David B Lombard

Richard L Frock

Katrin F Chua

Described herein are compositions (e.g. cells and transgenic animals) and methods relating to engineered Ig loci that permit expression of particular antibodies or antibody segments while still permitting recombination and/or maturation process for antibody optimization.

High-throughput mouse model for optimizing antibody affinities

Described herein are novel anti-PD1 antibody reagents (e.g., antibodies, antigen-binding fragments thereof, and/or chimeric antigen receptors). Also described herein antibody-drug conjugates or kits comprising the disclosed antibody reagents, as well as methods of treating cancer by administering the disclosed antibody reagents.

Methods and compositions relating to anti-PD1 antibody reagents

Described herein are methods and systems relating to high throughput, genome-wide translocation sequencing (HTGTS) and/or detection of double-stranded DNA break (DSB) locations. The methods described herein can comprise generating DSBs in a nucleic acid sequence and performing nested PCR with the primers described herein. Described herein is an enhanced HTGTS approach. The assays and methods described herein permit the measurement of various DNA double-strand break (DSB) activities either intrinsic to the biological system or from outside agents.

Methods relating to the detection of recurrent and non-specific double strand breaks in the genome

Provided are methods for high-throughput screening to determine locations of double-stranded DNA breaks (DSBs) and translocations in genomes caused by different agents, such as enzymes.

High throughput genome-wide translocation sequencing

The present invention is directed to methods for enhancing the replicative capacity of cells, by culturing the cells in the presence of an active agent or compound which inhibits SIRT1. One method provides expanding stem cells by culturing the cells in the presence of a SIRT1 inhibitor. The resulting cultured cells can be used for a variety of applications including cell-based therapies such as bone marrow transplants, gene therapies, tissue engineering, and in vitro organogenesis.

Growing community of inventors

Cambridge, MA, United States of America

Frederick W Alt